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Abstract 27 
Embryonic mammary cells are a unique population comprised of 28 
undifferentiated, highly plastic progenitor cells that create normal mammary 29 
tissues. The mammary gland continues to develop after birth from 30 
descendants of embryonic mammary cells. Here, we establish novel cell lines 31 
from mouse mammary organs, immediately after they formed during prenatal 32 
development, to facilitate studies of primitive mammary cells, which are 33 
difficult to isolate in sufficient quantities for use in functional experiments. We 34 
show some lines can be induced to secrete milk, a distinguishing feature of 35 
mammary epithelial cells. Targeted deletion of Sox9, from one clone, leads to 36 
decreased ability to respond to lactogenic stimuli, consistent with a previously 37 
identified role for Sox9 in regulating luminal progenitor function. Sox9 ablation 38 
also leads to alterations in 3D morphology and downregulation of Zeb1, a key 39 
epithelial-mesenchymal transition regulator. Prenatal mammary cell lines are 40 
an invaluable resource to study regulation of mammary progenitor cell biology 41 
and development.  42 
43 
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Introduction 44 
Embryonic breast epithelial cells are a unique cell population comprised of 45 
undifferentiated and highly plastic progenitor cells that ultimately give rise to 46 
all other postnatal breast epithelial cells. Lineage tracing studies have 47 
indicated that embryonic mammary cells are multipotent in vivo1-3. An 48 
important area of research in mammary gland biology is to determine the 49 
roles of genes and signalling pathways that regulate embryonic stages of 50 
mammary gland development, as many of these are also relevant to 51 
processes that are deregulated in cancer4,5. Despite their relevance to breast 52 
cancer research, the routine use of primary mid-gestation embryonic 53 
mammary cells for functional study is not currently feasible, due to the small 54 
size of the nascent organ.  55 
In mice, mammary gland development commences at embryonic day 56 
11 (E11) with the sequential appearance of five pairs of mammary primordia6. 57 
Local epithelial thickenings invaginate to the underlying tissue to form buds, 58 
which from E12.5 onwards are surrounded by a specialized condensed 59 
mammary mesenchyme. Mammary buds grow relatively slowly in size until 60 
E14 when the epithelial cells within the bud start to proliferate extensively and 61 
then invade into the underlying mesenchymal tissues6. These early stages of 62 
development are of particular interest as the cells have a number of unique 63 
properties. The epithelial cells within the E11-E13 stage mammary organ are 64 
largely quiescent7,8. At these stages of development, epithelial cells are 65 
thought to accrue within the mammary organ via localised cell movements9,10. 66 
Dissociated embryonic mammary cells from E12-E13-stage organs have 67 
minimal ability to efficiently repopulate cleared mammary fat pads, whilst cells 68 
from E16-18-stage organs have a much higher ability to engraft11,12. Intact 69 
mammary bud epithelium from E13-stage embryos can repopulate cleared fat 70 
pads suggesting a stem cell population has been delimited by mid-gestation13. 71 
Recent results from lineage tracing experiments indicate that embryonic 72 
mammary cells at E12-E13 stages are multipotent at the cellular level and 73 
become lineage-restricted prior to birth1-3. Although embryonic mammary 74 
progenitor cells from E12-13-stages harbour very distinct biological properties 75 
from embryonic mammary progenitor cells isolated from E16-17-stages and 76 
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from the postnatal mammary gland, a lack of appropriate in vitro models has 77 
limited their accessibility for many researchers. 78 
Most studies of the embryonic mammary gland have relied on analyses 79 
of embryos from genetically modified mice or embryonic mammary organ 80 
explant cultures14-17. These methods require considerable training, expertise 81 
and the use of animals. However, using these novel embryonic mammary cell 82 
lines and standard two- and three-dimensional culture techniques, we model 83 
several key aspects of embryonic mammary gland development in vitro. Using 84 
CRISPR-Cas9 genome editing, we investigate the role of Sox9, an embryonic 85 
Sox transcription factor, which has been implicated in conferring stem cell 86 
state to differentiated postnatal mammary epithelial cells18, in the regulation of 87 
stem cell activity and the differentiation potential of cells formed during early 88 
stages of embryonic mammary gland development.  Our findings highlight the 89 
distinct biological features and context dependent regulation of embryonic 90 
mammary progenitor cells and are a novel resource for studying this unique 91 
cell population. 92 
 93 
 94 
 95 
 96 
 97 
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Results 99 
Novel embryonic mammary progenitor cell lines established  100 
To date, the establishment and maintenance of primary mammary embryonic 101 
epithelial cell cultures from mouse embryos at stages between E12-13 has 102 
not been possible. To overcome this issue, we have taken advantage of the 103 
Immortomouse, a genetically modified mouse, to introduce a temperature-104 
sensitive Simian virus (SV) 40 antigen under control of an interferon regulated 105 
promoter that enables immortalisation of certain types of cells, including 106 
epithelial and mesenchymal cells19. Immortomice were bred with s-SHIP-GFP 107 
mice, which GFP expression marks epithelial progenitor cells, including those 108 
in the embryonic mammary primordia to facilitate and confirm dissection of the 109 
mammary organ when it is first morphologically distinct20. The majority of s-110 
SHIP-GFP embryonic mammary epithelial cells are GFP+ and adjacent 111 
embryonic mammary mesenchymal cells are GFP- (Figure 1A and 112 
Supplementary Fig. 1A). Mammary primordia number three were 113 
microdissected from E12.0-stage embryos so that the mammary epithelium, 114 
mammary mesenchyme, and fat pad precursors were isolated and such that 115 
other GFP+ cell types marked in s-SHIP-GFP embryos21 were excluded 116 
(Figure 1A). Excised mammary organs were embedded in thick Basement 117 
Membrane Extract (BME) for a month, so that embryonic mammary progenitor 118 
cells (eMPC) from the mammary organoid were able to proliferate (Figure 1B). 119 
This adaptation period appeared to be important for successful cell isolation 120 
since enzymatic digestion of Immorto:s-SHIP-GFP mammary organs 121 
immediately after microdissection did not give rise to cultivable eMPCs 122 
beyond one month. After proliferating for one month, eMPCs were harvested 123 
by enzymatically digesting the organoid culture grown in thick BME and 124 
expanding the cells in two-dimension culture. The bulk cells of this expanded 125 
eMPC are referred to subsequently as ePool (Figure 1B). To obtain clonal cell 126 
lines, single ePool cells were separated using fluorescence-activated cell 127 
sorter (FACS) according to s-SHIP-GFP expression status (GFP+ or GFP-) at 128 
the time of sorting (Figure 1B and Supplementary Fig. 1B). ~9% of GFP+ and 129 
~2% of GFP- cells gave rise to viable clones.  Sixteen clones were derived 130 
from the GFP+ fraction (designated eG1, eG2, eG2E9, etc). e1 and e2 were 131 
the only clones that survived from GFP- fraction (Supplementary Fig. 1C). 132 
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However, GFP expression is not necessarily indicative of tissue of origin since 133 
the activity of s-SHIP promoter is variable in cell populations expanded in 2D 134 
culture. eMPC clones expanded from single s-SHIP-GFP+ or single s-SHIP-135 
GFP- cells contain both GFP+ and GFP- cells upon passage in 2D culture 136 
(Supplementary Fig. 1C).  137 
Hierarchical cluster analysis of gene expression profiles obtained by 138 
RNA sequencing shows that eMPCs are distinct from other types of 139 
progenitor and stem cells, including embryonic stem cells (ESC), mouse 140 
embryonic fibroblasts (MEF), mesenchymal stem cells (MSC) and bone 141 
marrow mononuclear cells (BMMC) (Figure 2A). From 17204 significantly 142 
modulated genes, the 2059 most highly variable were selected when DESeq2 143 
software was employed with the Likelihood ratio test (LRT), and using the 144 
intensity difference test (detailed selection strategy and gene lists are in 145 
Supplementary Dataset 1). Principal component analysis (PCA), based on 92 146 
genes, produces a similar clustering of the eMPC clones with other stem cell 147 
types (Figure 2B and Supplementary Dataset 1). 148 
Mammary organs from C57BL/6 E12.5-stage mouse embryos were 149 
microdissected so that mammary epithelium, mammary stroma (mammary 150 
mesenchyme, and adjacent fat pad precursor), and surface epithelium were 151 
separated and the tissues were used for gene expressing profiling using RNA-152 
sequencing. Hierarchical clustering based on transcriptome profiles of the 153 
separated embryonic mammary primordia tissues and eMPCs and other stem 154 
cell types was performed (Supplementary Fig. 2 and Supplementary Dataset 155 
2). To assess the global landscape of expression in this dataset, we 156 
performed PCA and 26 genes revealed clustering of eMPC lines into three 157 
distinct groups based on their expression of genes encoding Keratin and cell 158 
adhesion regulators (Figure 2C). Our previous results have shown that 159 
embryonic mammary cells are largely devoid of cells expressing differentiation 160 
markers, although a few cells present within the E12-stage embryonic 161 
mammary bud epithelium express stem cell/progenitor markers associated 162 
with mature postnatal mammary epithelial cell (MEC) lineages22. PCA 163 
identifies clusters based on expression of several genes, some of which 164 
control cell adhesion, including the protocadherin, Pcdh7, integrin, Itga3, and 165 
extracellular matrix (ECM) ligand, Lama4, that are highly expressed by a 166 
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subset of the cell lines (eG1, eG2C7, eG1C10), which also express Keratins 167 
(Krt7, Krt18, Krt19). These clones belonging to the cluster marked in green in 168 
Figure 2 may represent mammary epithelial progenitor cells. Clones 169 
belonging to another cluster, marked in yellow in Figure 2, including e1, which 170 
was selected further study, express high levels of a number of markers 171 
including, Cd34, Cd74, Ebf2, Fabp4, Runx2, and Sox9 that are associated 172 
with a variety of stem cell types23-28 and may represent less-differentiated 173 
progenitor/stem cells types. Two cells lines with less distinct features, (marked 174 
in orange in Figure 2), e2 and eG2 that cluster with the pool, were also 175 
selected for further study. eG1 was selected for further study since it 176 
expresses high levels of markers associated with an epithelial-state, including 177 
Keratins, the epithelial basement membrane protein Lamc2, and Lgr4, a 178 
regulator of mammary gland development and stem cell activity29.  179 
In total, two clones expanded from GFP+ cells (eG1 and eG2) and the 180 
two clones expanded from GFP- cells (e1 and e2) lines, along with the ePool, 181 
were used for further characterization based on their distinct morphologies, 182 
transcriptome profiles and cluster analysis results (Figure 3). The two GFP- 183 
cell lines (e1, e2) do not cluster together. However, single GFP+ and GFP- 184 
cells were expanded prior to other characterization including, RNA 185 
sequencing, and these cell populations contained a mixture of both GFP+ and 186 
GFP- cells (Supplementary Fig. 1C). 187 
We selected a subset of markers that have direct links to stem cell 188 
biology and confirmed the RNA sequencing profiles using qRT-PCR (Figure 189 
3B). We also used immunohistochemistry (IHC) to confirm expression of Sox9 190 
and Twist1 protein in specific eMPC clones (Figure 3C). Sox9 and Twist1 191 
protein expression were discordant with the RNA expression results, but 192 
mismatch between transcriptional and translational levels is a frequently 193 
occurring phenomena30. 194 
 195 
eMPCs harbour varying capacities for differentiation into the 196 
mesodermal lineage  197 
We examined the capacity of eG1, eG2, e1, e2 and the ePool to differentiate 198 
into mesodermal lineages. Cells were exposed to differentiation media, 199 
 8
previously reported to induce MSCs toward adipocyte or endothelial cell 200 
lineages. Under adipogenic conditions, only e1 cells produced lipid-filled 201 
adipocytes in a substantial fraction of cells, indicating notable adipogenic 202 
ability, whereas eG1 and eG2 do not respond to adipogenic stimuli. (Figure 203 
4A). Under endotheliogenic conditions, e1, eG2 and the ePool formed tubular 204 
network comparable to control Human umbilical vein endothelial cells 205 
(HUVECs) cultured in endothelium growth medium (Figure 4B). Both e1 and 206 
eG2 express a vascular progenitor cell marker Cd34 prior to induction (Figure 207 
3A). Overall, these functional studies  suggest that clone e1 is the most 208 
responsive of the four cell lines to  mesodermal lineage differentiation cues. 209 
 210 
eMPCs are clonogenic and form distinct sphere morphologies  211 
eG1, eG2, e1, e2, and the ePool were evaluated for mammary sphere-212 
forming ability using the standard sphere formation technique. Each clone 213 
was cultured under sphere-forming conditions and formed spheres with highly 214 
distinct morphologies (Figure 5A). All eMPCs formed spheres, although e1 215 
had the highest sphere-forming rate (3.93%) and eG1 the lowest (0.69%) 216 
(Figure 5B). Two clones (e1, eG1) were selected for more detailed functional 217 
assessments based on their distinct responses in functional assays and 218 
marker profiles. eG1 spheres show higher form factor, a measure of 219 
sphericity, when compared to those of e1, suggesting that eG1 spheres are 220 
relatively compact compared to the spheres formed from the other clones 221 
(Figure 5C-D). e1 cells had limited engraftment ability when injected into 222 
cleared mammary fat pads (Supplementary Figure 3). No teratoma formation 223 
was observed, as would be expected to occur after xenografting of ESC cells. 224 
 225 
eMPCs form differentiated mammary acini in vitro 226 
eMPCs were evaluated for their ability to undergo functional alveolar 227 
differentiation by assessing cellular production of milk proteins by 228 
immunofluorescence staining with an antibody that detects milk specific 229 
proteins including, β-casein, free secretory component, and lactoferrin. 230 
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eMPCs were grown using conditions that  induce lactogenic differentiation of 231 
mammary cells with prolactin. Under these conditions, e1, eG1, eG2 and 232 
ePool formed domes that produce milk protein, indicative of lactogenic 233 
differentiation (Figure 6A). In these assays, e1 and ePool produced the 234 
greatest number of alveoli-like structures, with an alveologenic capacity to 235 
produce milk similar to postnatal MECs. eG1, and eG2 also showed 236 
lactogenic ability, but it was not possible to directly compare with the others 237 
since it was not possible to maintain the confluent cell culture needed for 238 
assessment at identical timepoints with this assay (Figure 6B). 239 
 240 
Sox9 ablation in e1 leads to reduced expression of Zeb1 241 
Mammary tissues originate from multipotent embryonic progenitors, 242 
which give rise to unipotent basal and luminal stem cells found and postnatal 243 
mammary tissues31. Sox9 was selected for further study since it is amongst 244 
the earliest transcription factors expressed by cells within the embryonic 245 
mammary epithelium and its expression increases so that most cells express 246 
high levels of Sox9 by E14.5 (Supplementary Fig. 4)22. We assessed the role 247 
of Sox9 in regulating embryonic mammary stem cell function using e1, a line 248 
that expresses a number of markers typically associated with stem/progenitor 249 
cells, including high levels of Sox9. CRISPR-Cas9 was used to create 3 250 
independent subclones with gene deletions (or knockouts (KO)) of Sox9 251 
derived from e1, e1/Sox9-KO#1, e1/Sox9-KO#2, and e1-Sox9-KO#3 (Figure 252 
7A). 253 
We confirmed a reduction in Sox9 levels in the 3 subclones with Sox9 254 
deletions compared to non-targeting guide control cells by qRT-PCR (Figure 255 
7B), immunohistochemistry (Figure 7C), and western blotting (Supplementary 256 
Fig. 5B). We also detected a marked reduction of expression of Zeb1, a key 257 
epithelial-to-mesenchymal transition (EMT) regulator, and concomitant with 258 
the level of reduction of Sox9 (Figure 7B). Using IHC, we confirmed total loss 259 
of Sox9 expression in e1/Sox9-KO#1 subclone, but detected Sox9+ cells in 1-260 
4%  of e1/Sox9-KO#2 and e1/Sox9-KO#3 cells (Figure 7C). Reduced 261 
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detection of Sox9 in the 3 Sox9-KO subclones is correlated with reduction of 262 
Zeb1-expressing cells (Figure 7C).  263 
 264 
Sox9 ablation increases e1 clonogenicity 265 
In non-targeting guide control cells derived from e1, (e1/Co#1 and 266 
e1/Co#2), sphere-forming efficiency is similar in both the parental e1 clone 267 
and non-targeted e1 subclones (Figure 5B and 7D). In all three 268 
independently-derived e1 subclones with Sox9 deletions, sphere-forming 269 
efficiencies increased by approximately two-fold, indicating that deletion of 270 
Sox9 in e1 enhances clonogenic ability, a measure of stem cell activity 271 
(Figure 7D). When plated as multicellular aggregates on low-attachment 272 
plates, no change in spheroid morphology is observed (Supplementary Fig. 273 
6). However, when spheroids are embedded with BME or matrigel, the 274 
spheroids from Sox9-KO cells are larger and exhibit a greater number of 275 
cellular protrusions when compared to controls indicative of altered 276 
morphogenetic and enhanced migratory capacity (Figure 7E-F and 277 
Supplementary Figure 6).  278 
 279 
Sox9 ablation decreases response to lactogenic stimuli  280 
We assessed expression of several stem/lineage markers in e1/Sox9-281 
KO#1, which lacks detectable Sox9 when cells are stained by IHC. Acta2 (α-282 
SMA), a marker normally expressed by basal stem cells and differentiated 283 
myoepithelial cells, was increased when Sox9 was ablated. Levels of Procr, a 284 
marker for a rare basal mammary stem cell population and Trp63, a basal cell 285 
marker, were both decreased, suggesting profound alterations of the basal 286 
features of these cells (Figure 8A). We found other EMT regulators including, 287 
Snail2/Slug and Twist were expressed at lower levels in cells lacking Sox9, 288 
whilst E-cadherin levels, an epithelial marker, were slightly increased, 289 
consistent with a reduced EMT signature that would be expected from 290 
reduced Zeb1 levels.   291 
RNA sequencing analysis confirmed that Sox9 transcripts were not 292 
completely deleted from the three e1/Sox9-KO subclones. This was 293 
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anticipated since the targeting strategy does not remove the 5’ transcript, 294 
including ATG start codon). e1/Sox9-KO#1 expresses the lowest Sox9 levels 295 
compared to e1/Sox9-KO#2 and -KO#3 which show reduced Sox9 levels 296 
compared to control cells (Supplementary Fig. 7). A small number of genes 297 
were consistently up- and down-regulated in all three e1/Sox9-KO lines when 298 
compared to e1/control subclones in transcriptomic analysis (Figure 8B). One 299 
is Csf1, which promotes postnatal mammary stem cell activity, and is 300 
expressed at higher levels in all Sox9-deficient e1 subclones. Two clusters of 301 
interest were identified after clustering of all hits identified based on either 302 
DESeq or Intensity Difference tests. One group includes Sox9, whilst the 303 
other group displays the opposite expression pattern. e1/Sox9-KO#1 and 304 
e1/Sox9-KO#3 clustered more closely together than with e1/Sox9-KO#2, and 305 
both lines displayed pronounced changes in morphologies when cultured in 306 
3D, so these two lines were analysed together to identify genes consistently 307 
modulated in these e1/Sox9-KO cells compared to the control cells. Genes 308 
associated with innate immunity, cholesterol biosynthesis, cell fate are down-309 
regulated, while genes regulating cell adhesion, Rap1 signalling and kinase 310 
activity are upregulated in e1/Sox9-KO#1 and e1/Sox9-KO#3 cells, identifying 311 
potential regulators of the morphological changes observed when cultured in 312 
3D (Supplementary Dataset 3). 313 
Results from lineage tracing studies have shown Sox9+ cells contribute 314 
to alveologenesis32. We therefore investigated the ability of e1/Sox9-KO cells 315 
to form fully differentiated mammary acini and secrete milk using an in vitro 316 
assay. Fewer alveoli-like structures derived from e1/Sox9-KO cells formed 317 
from all three e1/Sox9-KO lines and these were smaller and ill-defined 318 
structures compared to those formed from e1/control cells (Figure 8C-D). Our 319 
results demonstrate a diminished ability of e1/Sox9-KO embryonic mammary 320 
cells to respond to lactogenic stimuli and undergo functional alveologenesis. 321 
These results indicate Sox9 expression is required for embryonic mammary 322 
progenitor cells to attain a mature luminal progenitor cell phenotype capable 323 
of efficiently differentiating to form fully functional alveoli. 324 
325 
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Discussion 326 
In this study, we have established eighteen novel, cultivable, embryonic 327 
mammary progenitor cell lines (eMPCs). eMPCs will be a valuable resource 328 
for studying molecular regulators of normal breast development and 329 
understanding mammary cell fate and its plasticity. Based on gene expression 330 
and principal component analysis of the embryonic mammary progenitor cell 331 
lines, we identified three major clusters. One cluster (marked in yellow in 332 
Figure 2 and eleven out of the sixteen clones) is likely to represent mammary 333 
epithelial progenitor cells in an undifferentiated, plastic state since these cells 334 
express high levels of several stem cell makers; another cluster of 3 clones 335 
(marked in green in Figure 2) is likely to be representing more differentiated 336 
epithelial mammary progenitor cells since cells from this cluster express 337 
higher levels of Keratins. The third cluster of two clones and the pool (marked 338 
in magenta in Figure 2) appears to be composed of less plastic progenitor 339 
cells with restricted developmental potential. Four of the eighteen cell lines 340 
were selected for use in plasticity assays to represent the three major clusters 341 
and included both GFP- clones we had derived from single GFP- cells, as well 342 
as two of the sixteen GFP+ clones derived from single GFP+ cells. Although 343 
GFP+ expression was retained within the epithelial-appearing component 344 
after sustained organoid culture of the microdissected mammary organ, GFP 345 
expression is variable after expansion in 2D culture such that both GFP+ and 346 
GFP- cells are present in all eMPC lines, and we cannot assume GFP+ 347 
clones are derived from embryonic mammary epithelial cells or that GFP- 348 
cells represent mesenchymal cells.  We cannot exclude the possibility that 349 
GFP+ clones could have originated from other GFP+ cells present within the 350 
embryo although our dissection protocol should exclude this possiblilty21. In 351 
addition, we observe a small percentage of cells that lack GFP expression 352 
within the mammary primordial epithelium. 353 
Embryonic mammary lineage commitment is not completely 354 
understood33. It is still not clear how plastic or committed embryonic 355 
mammary cells are after removal from their native microenvironment. A 356 
subset of clones appeared to give rise to cell lines with mammary epithelial 357 
progenitor features and other clones appear less differentiated and more 358 
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plastic. Another small group clustered together with the ePool suggesting it 359 
consisted of a mixture of cell types. Heterogeneity exists between the clone 360 
profiles and their properties. This may reflect different levels of commitment of 361 
individual cells to the mammary lineage or loss of mammary epithelial 362 
phenotype. In addition, stem cells exist in a variety or spectrum of cell states 363 
that can interconvert34,35, so the observed heterogeneity could represent lines 364 
comprised of various components of a mammary progenitor spectrum. 365 
During embryonic development, tissues reshape during a combination 366 
of morphogenetic processes. Tissue compaction is a morphogenetic process 367 
by which a tissue adopts a tighter structure. Both cell adhesion and cell 368 
contraction play roles in tissue compaction36. Of the four clones assayed, only 369 
eG1, a line that expresses Keratins, as well as other adhesion regulators 370 
(including protocadherins, integrins, ECM ligands) undergoes compaction. 371 
eMPC are clonogenic and form mammary acini in vitro. All four of the eMPC 372 
lines tested can be induced to secrete milk with the appropriate hormonal 373 
stimulation (although e2 and eG2 with low efficiency), which demonstrates 374 
these cells have been committed to the mammary lineage, an event that 375 
occurs during embryonic development6. Clone e1 displayed limited ability to 376 
engraft in cleared mammary fat pads; this is consistent with other reports that 377 
found dissociated mid-gestation stage mouse mammary cells have very low 378 
stem cell activity when assessed using the cleared fat pad assay12. Baseline 379 
sequencing permits monitoring for changes after passage and we have been 380 
able to recluster eMPC cells together after early and later passages when re-381 
sequenced, suggesting these cells can be maintained without substantial 382 
changes. 383 
Sox9 is amongst the earliest transcription factors expressed by cells 384 
within the prenatal mammary epithelium22. Sox9 is also expressed by basal 385 
and luminal Estrogen Receptor (ER)- postnatal mammary epithelial cells32,37. 386 
Sox9 is thought to act together with Slug to confer a stem cell state to 387 
postnatal mammary epithelial cells18. Regulation of prenatal and postnatal 388 
mammary stem cell function by Sox9 produces distinct effects on clonogenic 389 
ability. In contrast to our finding of increased sphere-forming ability in e1 after 390 
Sox9 deletion, knockdown of Sox9 in primary postnatal mouse MECs causes 391 
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a marked reduction in organoid-forming ability, reduced Slug levels, and 392 
diminishes gland-reconstituting activity18. Impaired ability to undergo EMT is 393 
likely to be a common feature in all Sox9-deficient mammary cells. Mammary 394 
stem cell function is highly impacted by Sox9, but cell context also appears to 395 
be a significant factor, including developmental stage and state. A recent 396 
study shows a role for SOX9 in the regulation of hormone resistance in breast 397 
cancer38, highlighting the relevance of embryonic mammary factor expression 398 
in breast cancers and the need for further investigations into their ability to 399 
modulate cell states. 400 
Cell state is thought to influence epithelial cell phenotype and 401 
plasticity39. Mature postnatal MECs express Keratins, indicative of being in an 402 
epithelial state (E).  Loss of Sox9 and ability to undergo EMT in postnatal 403 
MECs should push them towards a more highly epithelial state, which, in 404 
theory, would have less stem cell activity according to several recent 405 
models40. Stem cell activity is thought to be highest when cells are in an 406 
intermediate epithelial/mesenchymal state35. Deleting Sox9 from e1 leads to 407 
reduced Zeb1 levels and reduced propensity to undergo EMT. As a result, e1/ 408 
Sox9-KO cells would be expected to shift from the embryonic mesenchymal 409 
(M) state towards epithelial to an intermediate hybrid M/E state, which, in 410 
theory, should have more stem cell activity and mixed epithelial (adhesive) 411 
and mesenchymal (migratory) properties that confer ability to move 412 
collectively as clusters (Supplementary Fig. 8)41,42. Our results clearly show 413 
that there are profound differences between the effects from loss of Sox9 414 
function on clonogenic ability in embryonic mammary progenitor cells 415 
compared to postnatal MECs, which exist in relatively high epithelial cell 416 
states. Despite these differences, these findings are consistent with current 417 
models of EMT/MET mediation of cell state in regulating stem cell function. 418 
Analysis from lineage tracing data indicated that Sox9 marks luminal 419 
progenitors that give rise to alveolar progenitors32. Fewer alveoli-like 420 
structures formed from e1/Sox9-KO cells and were smaller than control 421 
alveoli, which is consistent with a requirement for active Sox9 signallling in 422 
luminal progenitors to produce functional alveoli. Sox9 is required for luminal 423 
progenitor cell survival, but basal/myoepithelial cells can withstand loss of 424 
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Sox9 in studies using a conditional deletion of Sox9 from the mammary gland 425 
using Mouse mammary tumour virus (MMTV)-Cre37. Mice with Sox9-deficient 426 
mammary glands could lactate normally, but mosaic MMTV-Cre mediated 427 
gene deletion was reported, so it is likely that sufficient numbers of Sox9+ 428 
luminal progenitors were retained to produce functional alveoli that had 429 
undergone terminal differentiation37. Our results support a model in which 430 
Sox9 is required for the specification of mammary progenitor cells from early 431 
embryonic stages of through postnatal development as a key regulator of 432 
mammary gland development and luminal progenitor homeostasis and 433 
maintenance.  434 
Our study reveals complex interactions that underlie mammary lineage 435 
regulation, cell state and progenitor cell activity. Plasticity, defined as the 436 
ability of cells to dynamically change cell state, is crucial for many processes 437 
during mammary gland development and tissue homeostasis. Reversible 438 
EMT is central to tissue development, epithelial stemness, and cancer 439 
metastasis. SOX9 has been linked to all three of these processes18,37,43.  440 
Cell context is key in studies of mammary cell function and embryonic 441 
cells are highly plastic and multipotent, giving rise to both basal and luminal 442 
postnatal mammary cells. Cancer progression involves the loss of 443 
differentiated phenotype and acquisition of progenitor/stem cell features, 444 
which have recently been put forward as a hallmark of cancer44. These cell 445 
lines will be an invaluable resource to explore unresolved questions related to 446 
biology of mammary progenitor and stem cells, including those relevant to the 447 
origin of breast cancer. 448 
 449 
450 
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Methods 451 
Animal experiments 452 
All animal work was carried out under UK Home Office project and personal 453 
licenses following local ethical approval from The Institute of Cancer 454 
Research Ethics Committee and in accordance with local and national 455 
guidelines. Female mice (Mus musculus) were used for all experiments 456 
except breeding. Immortomouse and SCID/Beige mice were purchased from 457 
Charles River (Harlow, UK). s-SHIP-GFP mice were a gift from the late 458 
Professor Larry Rohrschneider (Fred Hutchinson Cancer Research Center, 459 
Seattle, WA, USA). Mice were housed in IVC cages on a 12h light/dark cycle 460 
and received food and water ad libitum. Mouse genotyping for detecting 461 
Immorto and s-SHIP-GFP transgenes was performed at Transnetyx (Cordova, 462 
TN, USA) and the results were used for colony maintenance. 463 
 464 
Isolation and culture of eMPC  465 
Immortomouse were backcrossed with C57BL6/J (B6) for four generations. 466 
The Immortomouse and s-SHIP-GFP mice were bred to obtain Immorto:s-467 
SHIP-GFP embryo. E12.0-stage Immorto:s-SHIP-GFP embryo was dissected 468 
to isolate only the organ of mammary primordium number three as a micro-469 
tissue, using Dumont #5 forceps and Tübingen Spring Scissors (Fine Science 470 
Tools GmbH, Heidelberg, Germany) using a Leica M205FA fluorescent 471 
stereomicroscope (Leica, Wetzlar, Germany). The remaining embryonic tissue 472 
was used for genotyping the Immorto transgene. Micro-tissue was 473 
immediately embedded into 200 μl of ice-cold Cultrex BME type 1, stem cell 474 
qualified, growth factor reduced (3434-005-02, AMS Biotechnology Ltd, 475 
Abingdon, Oxford, UK) within a well of a 48-well plate. The matrix-embedded 476 
tissue was transferred into CO2 incubator equilibrated to 33⁰C, 5% CO2 477 
atmosphere for 3 hours. Culture medium was overlaid on the solidified BME 478 
during the pre-incubation. Culture medium contains Mesencult MSC basal 479 
medium for mouse (05501), Mesencult Stimulatory Supplements for Mouse 480 
(05502), 2 mM L-Glutamine (17100; all from STEMCELL Technologies UK 481 
Ltd., Cambridge, UK), 5 U/ml Mouse Interferon gamma (IFNγ) (315-05, Pepro 482 
Tech EC Ltd., London, UK), and 0.1 mg/ml Primocin (ant-pm1, Source 483 
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Bioscience, Nottigham, UK). eMPCs migrated and proliferated within BME 484 
from the Immorto:s-SHIP-GFP micro-tissue for 1 month. Cells were harvested 485 
by trypsinisation and further expanded on two-dimensional dishes pre-coated 486 
thinly with BME, and referred to henceforth, as eMPC pool, abbreviated as 487 
ePool.  488 
 489 
Generation of eMPC clones 490 
Fluorescence activated cell sorting  491 
ePool cells were harvested from the culture dish and adjusted to the 492 
concentration of 2 x 106 cells/ml with PBS. To stain apoptotic and necrotic 493 
cells, cells were stained with DAPI at the final concentration of 1 μg/ml for 5 494 
min at room temperature prior to cell sorting. ePool were passed through a 40 495 
μm filter and sorted using BD Aria fluorescence-activated cell sorter (BD 496 
Biosciences, Oxford, UK). Live single ePool cells were positively gated using 497 
their forward and side scatter profiles (Supplementary Fig. 1B). ePool 498 
population with high s-SHIP-GFP expression and ePool GFP- population were 499 
subsequently gated based on green channel profile.  500 
Clone derivation from single cells 501 
Live single ePool GFP+ and ePool GFP- cells were individually sorted into 96 502 
multiwell plates. The multiwell plates were precoated with either Cultrex BME 503 
or Matrigel, growth factor reduced (734-0268, VWR International, Lutterworth, 504 
Leicestershire, UK) and filled with eMPC culture medium. The single cells on 505 
multiwell plates were incubated at CO2 incubator equilibrated to 33⁰C, 5% 506 
CO2 atmosphere without changing medium for a month. eMPC clones 507 
proliferated for a month after which they were trypsinised and transferred to 508 
dishes precoated with BME for further expansion. Only two GFP- eMPC 509 
clones were grown from a Matrigel-precoated multiwell plate and named as 510 
e1 and e2 (Figure 1B).  Fourteen GFP+ eMPC clones were recovered from 511 
two Matrigel-precoated multiwell plates, which are named as eG1, eG2, 512 
eG2E9…, depending on well position. Only one GFP+ eMPC clone, eG1B3, 513 
was recovered from a BME-precoated plate, suggesting that Matrigel is 514 
preferable for initial clonal cell expansion. 515 
 516 
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Cell culture 517 
The following mouse C57BL/6 (B6) cell lines were purchased and cultured for 518 
RNA isolation according to manufacturer’s instructions; Bone Marrow 519 
Mononuclear cells, (c57-6271F, Caltag Medsystems Buckingham, UK); 520 
Embryonic Stem Cells, (SCRC-1002, LGC standards, Middlesex, UK); Mouse 521 
Embryonic Fibroblasts, untreated, (GSC-6002, AMS Biotechnology Ltd); 522 
Mesenchymal Stem cells, (MUBMX-01001 Cambridge Bioscience, 523 
Cambridge, UK).  B6 postnatal mammary epithelial cells were isolated as 524 
described45. The mammary epithelial fraction was further purified using 525 
EasySep Mouse Epithelial Cell Enrichment Kit according to manufacturer’s 526 
instructions (19758, STEMCELL Technologies UK). Human Umbilical Vein 527 
Endothelial Cells were cultured according to manufacturer’s instruction 528 
(191027, Lonza, Basel, Switzerland). 529 
 530 
Total RNA isolation and quality control 531 
Embryonic mammary tissues (embryonic mammary primordial epithelium 532 
(MPE), embryonic mammary stroma (includes mammary mesenchyme (MM) 533 
and fat pad precursor (FPP)), and surface epithelium (Epi), were micro-534 
dissected from E12.5 B6 mice following the protocol described in46. Total RNA 535 
from cells and mammary tissue were extracted using RNeasy Plus Micro kit 536 
and RNeasy Mini kit (74034 and 74104, respectively, Qiagen, Manchester, 537 
UK), RNA concentration and gDNA contamination were determined using 538 
Qubit 2.0 Fluorometer and accompanying kits (Thermo Fisher Scientific, 539 
Waltham, MA, USA). RNA samples highly contaminated with gDNA for more 540 
than 10% of RNA were treated with TURBO DNA-free Kit (AM1907, Thermo 541 
Fisher Scientific) and concentrated using RNA Clean and Concentrator-5 542 
(R1015, Zymo Research, Irvine, CA, USA). All samples were assessed for 543 
RNA quality using Agilent 2100 Bioanalyzer system (Agilent Technologies, 544 
Cheshire, UK) and confirmed that RNA Integrity Number was greater than 9.0. 545 
 546 
RNA sequencing 547 
cDNA library preparation was carried out at Oxford Genomics Centre, The 548 
Wellcome Trust Centre for Human Genetics using PolyA+ RNA enrichment 549 
method for total RNA from cultured cells and SMARTer method for total RNA 550 
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from embryonic mammary tissue, respectively. mRNA fraction was selected 551 
from the total RNA before conversion to cDNA. Second strand cDNA 552 
synthesis incorporated dUTP. The cDNA was end-repaired, A-tailed and 553 
adapter-ligated. Prior to amplification, samples underwent uridine digestion. 554 
The prepared libraries were size selected, multiplexed and quality checked 555 
before paired end sequencing over three lanes of a flow cell. Amplified cDNA 556 
from embryonic mammary tissues were generated by the SMARTer 557 
amplification kit. The cDNA was end-repaired, A-tailed, adapter-ligated and 558 
amplified. The prepared libraries were size selected, multiplexed and quality 559 
checked before paired end sequencing on four lanes of a flow cell. Data was 560 
aligned to the reference genome, mm10, and quality checked. 561 
RNA sequencing files were submitted to ArrayExpress as accession E-562 
MTAB-6846, MTAB-6856, E-MTAB-6859. FastQ files were truncated to a 563 
consistent length of 75bp using trim galore v0.4.3 and were then aligned 564 
against the mouse GRCm38 genome assembly using hisat2 v2.0.5 using 565 
options --no-mixed and --no-discordant. Mapped positions with MAPQ values 566 
of <20 were discarded. Gene expression was quantitated using the RNA-Seq 567 
quantitation pipeline in SeqMonk software v1.37.0 568 
(https://www.bioinformatics.babraham.ac.uk/projects/seqmonk/) in opposing 569 
strand specific library mode. For count based statistics, raw read counts over 570 
exons in each gene were used.  For visualisation and other statistics 571 
log2RPM (reads per million reads of library) expression values were used. 572 
Differentially expressed genes were selected based on passing two statistical 573 
filters -the DESeq2 Likelihood Ratio Test with a cutoff of p<0.05 following 574 
multiple testing correction and the SeqMonk Intensity Difference filter on 575 
log2RPM values with a sample size of 1% of all genes and a cutoff of p<0.05 576 
after multiple testing correction. Hierarchical clustering was performed on per-577 
gene median centred log2RPM expression values using Pearson’s 578 
correlation. Gene cluster separation was performed by segmenting the tree at 579 
an R value of 0.5.  Clusters containing <50 genes were discarded. PCA was 580 
performed on column centred log2RPM values without additional scaling.  581 
The intensity difference test used a locally matched subset of 1% of 582 
genes based on average expression. From these a local standard deviation in 583 
log2RPM difference values was calculated and used to calculate the 584 
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probability of the cumulative distribution function for a normal distribution with 585 
this standard deviation, using the observed difference in the gene being 586 
tested.  P-values were corrected for multiple testing using Benjamini and 587 
Hochberg multiple testing correction. 588 
 589 
cDNA synthesis and real-time quantitative reverse transcription PCR  590 
cDNA library from total RNA was synthesised using QuantiTect Reverse 591 
Transcription Kit (205310, Qiagen). Comparative CT (ΔΔCT) real-time 592 
quantitative PCR was performed using Taqman Gene Expression assays as 593 
previously described17 on either ABI Prism 7900HT sequence detection 594 
system (Applied Biosystems, Foster City, CA, USA) or QuantStudio 6 Flex 595 
system (Thermo Fisher Scientific). Actb was used as an endogenous control 596 
and fold change normalised to a comparator sample was calculated. The 597 
assay probes are listed in Supplementary Dataset 4. 598 
 599 
Antibodies 600 
Antibodies used for whole-mount immunofluorescence, 601 
immunohistochemistry, immunofluorescence, and western blotting in this 602 
study are listed in Supplementary Dataset 4. 603 
 604 
Adipogenesis assay 605 
eMPC and MSCs (positive control) were plated at 100% confluency in 606 
Osteogenic/Adipogenic Base Media (CCM007, Bio-Techne Ltd, Oxford, UK) 607 
containing 1 μg/ml Insulin, 0.5 mM 3-Isobutyl-1-methylxanthine and 0.25 mM 608 
Dexamethasone (19278, I5879 and D2915 from Sigma, Dorset, UK, 609 
respectively). After 6 days, cells were fixed with 4% Paraformaldehyde/PBS 610 
and lipid droplets were detected by HCS LipidTOX™ Red Neutral Lipid Stain 611 
(H34476, Thermo Fisher Scientific) at 1:200 in PBS. Lipid-labelled cells were 612 
photographed using EVOS FL fluorescent microscope equipped with 10x Plan 613 
LWD FL 0.30NA objective (Thermo Fisher Scientific). 614 
 615 
In vitro tube formation assay 616 
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Tube formation ability of eMPCs was examined following a published 617 
protocol47. Briefly, eMPCs, MSCs (negative control) and HUVECs (positive 618 
control) were plated at ~80% confluency using endothelial growth medium 619 
(EGM) (EBM-2 medium containing EGM-2 SingleQuot Kit, CC-3156 and CC-620 
3162 from Lonza, respectively). On the next day, 96 well plates filled with 50-621 
80 μl Cultrex BME were prepared on ice without forming air bubbles and pre-622 
incubated at CO2 incubator equilibrated to 37⁰C, 5% CO2 atmosphere to allow 623 
matrix gelation. Cells were harvested by trypsinisation and re-suspended at 624 
the concentration of 1.5 x 105 cells /ml in either endothelial basal medium 2 625 
(EBM-2) or EGM-2 medium. 100 μl of single cell suspension (containing total 626 
15,000 cells) was gently added on the top of BME gel. After incubation for 24 627 
hours, cells were labelled with Calcein AM solution at the final concentration 628 
of 2 μM in EBM-2 medium and incubated in CO2 incubator for 30 min. Calcein 629 
AM-labelled cells were photographed using EVOS FL fluorescent microscope 630 
equipped with 2x Plan LWD 0.06NA objective (Thermo Fisher Scientific). The 631 
fluorescent images were analysed to detect mesh structure using a developed 632 
package of ImageJ, Fiji48 (http://imagej.net/Fiji/Downloads), and its Plugin, 633 
Angiogenesis Analyzer (Carpentier G., Angiogenesis Analyzer for ImageJ 634 
(2012); 635 
https://imagej.nih.gov/ij/macros/toolsets/Angiogenesis%20Analyzer.txt). Cells 636 
were also tested for tube formation assay with EBM-2 medium containing 10 637 
mM Sulforaphane (angiogenic inhibitor, S4441, Merck KGaA, Darmstadt, 638 
Germany) as a control to observe its inhibitory effect on the assay. 639 
 640 
Mammary alveologenesis assay 641 
Lactogenic ability of eMPCs was examined following an established 642 
protocol49. Briefly, eMPCs and MECs (positive control) were plated at 100% 643 
confluent in RPMI 1640 medium (21875, Thermo Fisher Scientific) containing 644 
10% horse serum (16050-122, Thermo Fisher Scientific), 5 μg/ml Insulin, 10 645 
ng/ml EGF (236-EG-200, Bio-Techne Ltd), 10 mM HEPES (H0887, Sigma), 646 
and Primocin (Bioscience). On the following day, in order to withdraw the EGF 647 
and enhance differentiation, rather than cell proliferation, cell medium was 648 
changed to EGF- medium containing 5% horse serum, 10 mM HEPES, and 649 
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Primocin in RPMI 1640 medium. After 3 days, mammary alveologenesis was 650 
induced by replacement with priming medium (EGF- medium containing 5 651 
μg/ml mouse Prolactin (757908, Biolegend, London, UK), 5 μg/ml Insulin, and 652 
0.1 mM Dexamethasone). Cells were fixed with 4% Paraformaldehyde/PBS 6 653 
days after induction and stained with anti-Milk antibody and DAPI. Alveoli 654 
were photographed using EVOS FL microscope and the number of alveoli 655 
larger than 100 μm per 24 well was counted manually.  656 
  For studies of e1 with reduced Sox9 expression, the assay was 657 
modified since e1/Sox9-knockout cells detached upon induction of lactogenic 658 
differentiation using the standard assay. Cells were plated around 80-90% 659 
confluence in MesenCult Expansion medium with MesenCult supplement, 200 660 
mM L-Glutamine, 5 U/ml IFNγ (Pepro Tech) and 0.1mg/ml Primocin. Once 661 
cells reached 100% confluence (on day 4), cell medium was changed to RPMI 662 
1640 medium containing 5% horse serum, 10 mM HEPES, and Primocin. On 663 
day 5, mammary alveologenesis was induced with medium containing 5 μg/ml 664 
mouse Prolactin, 5 μg/ml Insulin, and 0.1 mM Dexamethasone. Induction 665 
medium was replenished every 3 days. On day 11, cells were fixed with 4% 666 
Paraformaldehyde/PBS and stained with anti-Milk antibody and DAPI. Alveoli 667 
were photographed using EVOS FL microscope and the number of alveoli in 668 
different size ranges were counted manually. 669 
 670 
Sphere-forming assays 671 
A clonogenic mammosphere protocol and media were adapted for eMPCs50. 672 
Mouse EpiCult-B complete medium (05610, STEMCELL Technologies) was 673 
supplemented with 0.6% Methylcellulose (HSC011, Bio-Techne Ltd), 20 ng/ml 674 
basic FGF (3139-FB-025/CF, Bio-Techne Ltd), 20 ng/ml EGF, 2% 675 
NeuroCult™ SM1 Without Vitamin A, 10 μg/ml Heparin, 1 μg/ml 676 
Hydrocortisone (05731, 07980, and 07926, respectively, from STEMCELL 677 
Technologies UK Ltd), 10 ug/ml Insulin, 5 U/ml Mouse IFNγ, and 0.1 mg/ml 678 
Primocin. Trypsinised eMPCs and MSCs were passed through 40 μm filter to 679 
make absolute single cell suspension and the cell number was adjusted to 2-4 680 
x 105 cells/ml. 10,000 cells were added into 2 ml of the supplemented Epicult-681 
B medium. Cells were pipetted thoroughly to be distributed homogenously 682 
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within the viscous Methylcellulose-containing medium and transferred into 683 
Corning ultra-low attachment 6 well (10154431, Fisher Scientific, 684 
Loughborough, UK). 6 well plates were incubated within a humidified box at 685 
33⁰C incubator for eMPCs and 37⁰C for MSCs, respectively. At day 7, sphere 686 
images were photographed and automatically scored using Single Colony 687 
Verification program in Celigo cytometer (Nexcelom Bioscience LLC, 688 
Lawrence, MA, USA). 689 
 690 
Spheroid growth in hydrogel 691 
For analysing 3D morphology, e1/control and e1/Sox9-KO cells were seeded 692 
with 5000 cells/well onto Corning Costar Ultra-Low Attachment 96 well plates 693 
(Corning Kennebunk ME, USA) filled with eMPC culture medium. On day 3, 694 
50 µl of Corning Matrigel Growth Factor Reduced Basement Membrane 695 
Matrix (356231) or Cultrex PathClear 3-D Culture Matrix RGF BME I (3434-696 
005) was added into each well (except control wells). Medium was 697 
replenished every 3 days. On day 9, 50 µl of 1% agarose was added to the 698 
control wells. All spheroids were subsequently fixed with 4% 699 
Paraformaldehyde (PFA)/PBS and were photographed using EVOS FL 700 
microscope. 701 
 702 
CRISPR/Cas9-mediated gene targeting of Sox9 703 
We took advantage of lentiviral transduction of Cas9 gene within eMPCs 704 
followed by transfection of pre-made CRISPR RNA (crRNA) and trans-705 
activating crRNA (tracrRNA) for genetic ablation of Sox9, which were 706 
purchased from GE Healthcare (Little Chalfont, UK). Edit-R Lentiviral Blast-707 
Cas9 Nuclease Particles (VCAS10128, Dharmacon, Lafayette, Colorado, 708 
USA) were transduced into e1 and Cas9-expressing e1 population was 709 
expanded with 10 μg/ml Blasticidin (ant-bl-1, Source Bioscience Nottingham, 710 
UK) from day 4 onward. 2 x 105 cells of Blasticidin-resistant e1 were seeded 711 
on 6 well and on the next day treated with 5 μl DharmaFECT 1 Transfection 712 
Reagent (T-2001-02, Dharmacon) together with 5 μl of 10 μM Edit-R 713 
CRISPR-Cas9 Synthetic tracrRNA (U-002000-20, Dharmacon) and 5 μl of 10 714 
μM Sox9-targeting crRNA or non-targeting crRNA. Cell populations with Sox9 715 
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mutations were screened by Heteroduplex formation assay using 716 
QuickExtract DNA Extraction Solution (QE0905T, Qiagen, Peterborough, UK) 717 
and EnGen™ Mutation Detection Kit (E3321S, New England Biolabs, Herts, 718 
UK) according to manufacturer’s instructions. We tested 4 different crRNA 719 
and the primer sets to detect mutation within each crRNA-binding region; 720 
details are provided in Supplementary Dataset 4C. 2 cell populations (Sox9-721 
01 and Sox9-02 in Supplementary Fig. 5A) that were verified for Sox9 722 
mutation were further sorted using BD Aria to develop single cell-derived 723 
subclones. 3 e1/Sox9-knockout (KO) subclones, KO#1, KO#2, and KO#3, 724 
produced no Sox9 expression detectable by Western blot (Supplementary 725 
Fig. 5B). These three e1/Sox9-KO subclones as well as two e1/control clones, 726 
Co#1 and Co#2, were used in this study. 727 
 728 
Mammary fat pad injection of e1 729 
To allow bioluminescence imaging of e1 cells, cells were labelled with 730 
carrying red-shifted Luciola Italica luciferase transgene using lentivirus 731 
particles, RediFect Red-FLuc-Puromycin (CLS960002, Perkin Elmer, 732 
Buckinghamshire, UK). The transduced e1/Red-FLuc cells were selected with 733 
5 μg/ml Puromycin for 3 weeks. e1/Red-FLuc cells were harvested and 734 
resuspended at a concentration of 1 x 106 cells/ml in PBS. 100 μl of cells were 735 
injected into both the left and right inguinal mammary fat pad number 4 of 10-736 
week-old SCID/Beige female mice. Mice were injected 100 μl of 15 mg/ml D-737 
Luciferin (119222, Perkin Elmer) in PBS intraperitoneally and imaged after 5 738 
min using IVIS Illumina II (Perkin Elmer). Engrafted mammary glands were 739 
harvested 1-2 weeks after mammary fat pad injections and fixed in 4% PFA in 740 
PBS for immunohistochemistry. 741 
 742 
Statistical Analysis 743 
The data in the graphs are presented as mean and the standard error of the 744 
mean. The data was analysed by two-tailed ANOVA, Student’s t-test, or two-745 
tailed, paired t-test using GraphPad Prism 7 software. P-value ≤ 0.0001 is 746 
considered as extremely significant (****), P ≤ 0.001 as highly significant (***), 747 
P ≤ 0.01 as very significant (**), P ≤ 0.05 as significant (*), and P > 0.05 as 748 
not significant (ns), respectively. 749 
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The authors declare that the data supporting the findings of this study are 752 
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available in Supplementary Dataset 5. 755 
756 
 26
References 757 
1 Van Keymeulen, A. & Blanpain, C. Tracing epithelial stem cells during 758 
development, homeostasis, and repair. The Journal of cell biology 197, 759 
575-584, doi:10.1083/jcb.201201041 (2012). 760 
2 Wuidart, A. et al. Early lineage segregation of multipotent embryonic 761 
mammary gland progenitors. Nat Cell Biol 20, 666-676, 762 
doi:10.1038/s41556-018-0095-2 (2018). 763 
3 Lilja, A. M. et al. Clonal analysis of Notch1-expressing cells reveals the 764 
existence of unipotent stem cells that retain long-term plasticity in the 765 
embryonic mammary gland. Nat Cell Biol 20, 677-687, 766 
doi:10.1038/s41556-018-0108-1 (2018). 767 
4 Zvelebil, M. et al. Embryonic mammary signature subsets are activated in 768 
Brca1-/- and basal-like breast cancers. Breast cancer research : BCR 15, 769 
R25, doi:10.1186/bcr3403 (2013). 770 
5 Howard, B. & Ashworth, A. Signalling pathways implicated in early 771 
mammary gland morphogenesis and breast cancer. PLoS Genet 2, e112, 772 
doi:10.1371/journal.pgen.0020112 (2006). 773 
6 Propper, A. Y., Howard, B. A. & Veltmaat, J. M. Prenatal morphogenesis of 774 
mammary glands in mouse and rabbit. Journal of mammary gland biology 775 
and neoplasia 18, 93-104, doi:10.1007/s10911-013-9298-0 (2013). 776 
7 Balinsky, B. On the developmental processes in mammary glands and 777 
other epidermal structures. Transactions of the Royal Society Edinburgh 778 
62, 1-31 (1949-1950). 779 
8 Lee, M. Y. et al. Ectodermal influx and cell hypertrophy provide early 780 
growth for all murine mammary rudiments, and are differentially 781 
regulated among them by Gli3. PloS one 6, e26242, 782 
doi:10.1371/journal.pone.0026242 (2011). 783 
9 Propper, A. Y. Wandering epithelial cells in the rabbit embryo milk line. A 784 
preliminary scanning electron microscope study. Developmental biology 785 
67, 225-231 (1978). 786 
10 Propper, A. Y., Howard, B. A. & Veltmaat, J. M. Prenatal Morphogenesis of 787 
Mammary Glands in Mouse and Rabbit. Journal of mammary gland biology 788 
and neoplasia, doi:10.1007/s10911-013-9298-0 (2013). 789 
11 Makarem, M. et al. Developmental changes in the in vitro activated 790 
regenerative activity of primitive mammary epithelial cells. PLoS Biol 11, 791 
e1001630, doi:10.1371/journal.pbio.1001630 (2013). 792 
12 Spike, B. T. et al. A mammary stem cell population identified and 793 
characterized in late embryogenesis reveals similarities to human breast 794 
cancer. Cell stem cell 10, 183-197, doi:10.1016/j.stem.2011.12.018 795 
(2012). 796 
13 Sakakura, T., Nishizuka, Y. & Dawe, C. J. Capacity of mammary fat pads of 797 
adult C3H/HeMs mice to interact morphogenetically with fetal mammary 798 
epithelium. J Natl Cancer Inst 63, 733-736 (1979). 799 
14 Voutilainen, M. et al. Ectodysplasin regulates hormone-independent 800 
mammary ductal morphogenesis via NF-kappaB. Proceedings of the 801 
National Academy of Sciences of the United States of America 109, 5744-802 
5749, doi:10.1073/pnas.1110627109 (2012). 803 
15 Hens, J. R. et al. BMP4 and PTHrP interact to stimulate ductal outgrowth 804 
during embryonic mammary development and to inhibit hair follicle 805 
 27
induction. Development 134, 1221-1230, doi:10.1242/dev.000182 806 
(2007). 807 
16 Veltmaat, J. M. et al. Gli3-mediated somitic Fgf10 expression gradients are 808 
required for the induction and patterning of mammary epithelium along 809 
the embryonic axes. Development 133, 2325-2335, 810 
doi:10.1242/dev.02394 (2006). 811 
17 Kogata, N., Oliemuller, E., Wansbury, O. & Howard, B. A. Neuregulin-3 812 
regulates epithelial progenitor cell positioning and specifies mammary 813 
phenotype. Stem Cells Dev 23, 2758-2770, doi:10.1089/scd.2014.0082 814 
(2014). 815 
18 Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem 816 
cell state. Cell 148, 1015-1028, doi:10.1016/j.cell.2012.02.008 (2012). 817 
19 Jat, P. S. et al. Direct derivation of conditionally immortal cell lines from an 818 
H-2Kb-tsA58 transgenic mouse. Proceedings of the National Academy of 819 
Sciences of the United States of America 88, 5096-5100 (1991). 820 
20 Rohrschneider, L. R., Custodio, J. M., Anderson, T. A., Miller, C. P. & Gu, H. 821 
The intron 5/6 promoter region of the ship1 gene regulates expression in 822 
stem/progenitor cells of the mouse embryo. Dev Biol 283, 503-521, 823 
doi:S0012-1606(05)00270-8 [pii] 824 
10.1016/j.ydbio.2005.04.032 (2005). 825 
21 Bai, L. & Rohrschneider, L. R. s-SHIP promoter expression marks activated 826 
stem cells in developing mouse mammary tissue. Genes Dev 24, 1882-827 
1892, doi:10.1101/gad.1932810 (2010). 828 
22 Wansbury, O. et al. Transcriptome analysis of embryonic mammary cells 829 
reveals insights into mammary lineage establishment. Breast Cancer 830 
Research 13, doi:Artn R79 831 
Doi 10.1186/Bcr2928 (2011). 832 
23 Sidney, L. E., Branch, M. J., Dunphy, S. E., Dua, H. S. & Hopkinson, A. Concise 833 
review: evidence for CD34 as a common marker for diverse progenitors. 834 
Stem Cells 32, 1380-1389, doi:10.1002/stem.1661 (2014). 835 
24 dos Santos, C. O. et al. Molecular hierarchy of mammary differentiation 836 
yields refined markers of mammary stem cells. Proc Natl Acad Sci U S A 837 
110, 7123-7130, doi:10.1073/pnas.1303919110 (2013). 838 
25 Qian, H. et al. Molecular characterization of prospectively isolated 839 
multipotent mesenchymal progenitors provides new insight into the 840 
cellular identity of mesenchymal stem cells in mouse bone marrow. Mol 841 
Cell Biol 33, 661-677, doi:10.1128/MCB.01287-12 (2013). 842 
26 Shan, T., Liu, W. & Kuang, S. Fatty acid binding protein 4 expression marks 843 
a population of adipocyte progenitors in white and brown adipose tissues. 844 
FASEB J 27, 277-287, doi:10.1096/fj.12-211516 (2013). 845 
27 Wang, C. Q., Jacob, B., Nah, G. S. & Osato, M. Runx family genes, niche, and 846 
stem cell quiescence. Blood Cells Mol Dis 44, 275-286, 847 
doi:10.1016/j.bcmd.2010.01.006 (2010). 848 
28 Jo, A. et al. The versatile functions of Sox9 in development, stem cells, and 849 
human diseases. Genes Dis 1, 149-161, doi:10.1016/j.gendis.2014.09.004 850 
(2014). 851 
29 Wang, Y. et al. Lgr4 regulates mammary gland development and stem cell 852 
activity through the pluripotency transcription factor Sox2. Stem Cells 31, 853 
1921-1931, doi:10.1002/stem.1438 (2013). 854 
 28
30 Liu, Y., Beyer, A. & Aebersold, R. On the Dependency of Cellular Protein 855 
Levels on mRNA Abundance. Cell 165, 535-550, 856 
doi:10.1016/j.cell.2016.03.014 (2016). 857 
31 Rodilla, V. et al. Luminal progenitors restrict their lineage potential during 858 
mammary gland development. PLoS Biol 13, e1002069, 859 
doi:10.1371/journal.pbio.1002069 (2015). 860 
32 Wang, C., Christin, J. R., Oktay, M. H. & Guo, W. Lineage-Biased Stem Cells 861 
Maintain Estrogen-Receptor-Positive and -Negative Mouse Mammary 862 
Luminal Lineages. Cell Rep 18, 2825-2835, 863 
doi:10.1016/j.celrep.2017.02.071 (2017). 864 
33 Howard, B. A. In the beginning: the establishment of the mammary lineage 865 
during embryogenesis. Seminars in cell & developmental biology 23, 574-866 
582, doi:10.1016/j.semcdb.2012.03.011 (2012). 867 
34 Liu, S. et al. Breast cancer stem cells transition between epithelial and 868 
mesenchymal states reflective of their normal counterparts. Stem Cell 869 
Reports 2, 78-91, doi:10.1016/j.stemcr.2013.11.009 (2014). 870 
35 Wahl, G. M. & Spike, B. T. Cell state plasticity, stem cells, EMT, and the 871 
generation of intra-tumoral heterogeneity. NPJ Breast Cancer 3, 14, 872 
doi:10.1038/s41523-017-0012-z (2017). 873 
36 Turlier, H. & Maitre, J. L. Mechanics of tissue compaction. Semin Cell Dev 874 
Biol 47-48, 110-117, doi:10.1016/j.semcdb.2015.08.001 (2015). 875 
37 Malhotra, G. K. et al. The role of Sox9 in mouse mammary gland 876 
development and maintenance of mammary stem and luminal progenitor 877 
cells. BMC Dev Biol 14, 47, doi:10.1186/s12861-014-0047-4 (2014). 878 
38 Jeselsohn, R. et al. Embryonic transcription factor SOX9 drives breast 879 
cancer endocrine resistance. Proc Natl Acad Sci U S A 114, E4482-E4491, 880 
doi:10.1073/pnas.1620993114 (2017). 881 
39 Varga, J. & Greten, F. R. Cell plasticity in epithelial homeostasis and 882 
tumorigenesis. Nat Cell Biol 19, 1133-1141, doi:10.1038/ncb3611 (2017). 883 
40 Hong, T. et al. An Ovol2-Zeb1 Mutual Inhibitory Circuit Governs 884 
Bidirectional and Multi-step Transition between Epithelial and 885 
Mesenchymal States. PLoS Comput Biol 11, e1004569, 886 
doi:10.1371/journal.pcbi.1004569 (2015). 887 
41 Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 888 
21-45, doi:10.1016/j.cell.2016.06.028 (2016). 889 
42 Revenu, C. & Gilmour, D. EMT 2.0: shaping epithelia through collective 890 
migration. Curr Opin Genet Dev 19, 338-342, 891 
doi:10.1016/j.gde.2009.04.007 (2009). 892 
43 Malladi, S. et al. Metastatic Latency and Immune Evasion through 893 
Autocrine Inhibition of WNT. Cell 165, 45-60, 894 
doi:10.1016/j.cell.2016.02.025 (2016). 895 
44 Malta, T. M. et al. Machine Learning Identifies Stemness Features 896 
Associated with Oncogenic Dedifferentiation. Cell 173, 338-354 e315, 897 
doi:10.1016/j.cell.2018.03.034 (2018). 898 
45 Smalley, M. J. Isolation, culture and analysis of mouse mammary epithelial 899 
cells. Methods Mol Biol 633, 139-170, doi:10.1007/978-1-59745-019-900 
5_11 (2010). 901 
46 Sun, L., Lee, M. Y. & Veltmaat, J. M. A non-enzymatic microsurgical 902 
dissection technique of mouse embryonic tissues for gene expression 903 
 29
profiling applications. Int J Dev Biol 55, 969-974, 904 
doi:10.1387/ijdb.113424ls (2011). 905 
47 Arnaoutova, I. & Kleinman, H. K. In vitro angiogenesis: endothelial cell 906 
tube formation on gelled basement membrane extract. Nat Protoc 5, 628-907 
635, doi:10.1038/nprot.2010.6 (2010). 908 
48 Schindelin, J. et al. Fiji: an open-source platform for biological-image 909 
analysis. Nat Methods 9, 676-682, doi:10.1038/nmeth.2019 (2012). 910 
49 Morrison, B. & Cutler, M. L. Mouse Mammary Epithelial Cells form 911 
Mammospheres During Lactogenic Differentiation. J Vis Exp, 912 
doi:10.3791/1265 (2009). 913 
50 Boras-Granic, K., Dann, P. & Wysolmerski, J. J. Embryonic cells contribute 914 
directly to the quiescent stem cell population in the adult mouse 915 
mammary gland. Breast Cancer Res 16, 487, doi:10.1186/s13058-014-916 
0487-6 (2014). 917 
918 
 30
Figure legends 919 
 920 
Figure 1. Establishment of novel embryonic mammary progenitor cell 921 
lines.  922 
(A) Schematic illustration of experimental scheme of eMPC derivation from 923 
E12.0-stage Immorto;s-SHIP-GFP mammary organ number three. After 924 
microdissection of MP3 to include three tissues: GFP+ MPE (GFP staining in 925 
green), GFP-, ERα+ MM (ERα staining in magenta) and adjacent ERα- FPP 926 
(DAPI staining in blue), MP3 was cultured on thick BME for 4 weeks. 927 
(B) Brightfield and GFP images of cultured MP3 at Day 1, Day 11, Day 25. 928 
After culture, a variety of cell types including lipid-containing adipocyte-like 929 
cells (area shown in black box and yellow arrow), as well as contractile 930 
muscle-like cells (black arrowhead) were observed within the cell population. 931 
After enzymatic dissociation, eMPC were plated and expanded in 2D culture 932 
to obtain a pool of eMPCs (ePool). eMPC cells were subject to single cell 933 
sorting into GFP+ and GFP- cell populations using fluorescence-activated cell 934 
sorting. Clones were expanded as single-cell derived clones to create the 935 
eighteen single cell-derived clones  from GFP- cells (e1 and e2) or GFP+ cells 936 
(eG1, eG2E9, etc.) described in this study. scale bar, 200 μm.  937 
MP3, mammary primordium 3, MPE, mammary primordial epithelium, Epi, 938 
epithelium, MM, mammary mesenchyme, FPP, fat pad precursor. eMPC, 939 
embryonic mammary progenitor cells (eMPC), BF, brightfield.  940 
 941 
Figure 2. Global gene expression landscape of novel embryonic 942 
mammary progenitor cell lines.  943 
 (A) Dendrograms from hierarchical clustering of RNA sequencing data using 944 
2059 most significantly-changing genes of eMPC and other types of 945 
progenitor/stem cells. Eighteen eMPC clones are classified into three main 946 
clusters, which are highlighted: e1 cluster (yellow box), e2/eG2/ePool cluster 947 
(magenta box), and eG1 cluster (green box).  948 
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(B) PCA of eMPC and other types of progenitor/stem cells. Loading plot using 949 
principal component (PC) 2 (18%) and PC3 (14%) of the 17,204 most variable 950 
genes. Three main eMPC clusters (yellow, magenta, and green) recapitulate 951 
the hierarchical clustering results shown in (B). The heatmap shows 952 
hierarchical clustering based on top 0.5% of PC2 (92 genes).  953 
 (C) PC1 and PC2 loading plot using the most highly significant genes in the 954 
dataset of eMPC and other progenitor/stem cells combined with embryonic 955 
mammary tissues. Three eMPC clusters (yellow, magenta, and green) and an 956 
embryonic mammary tissue cluster (purple) from PCA are highlighted based 957 
PC1. The heatmap shows results of hierarchical clustering based on 26 genes 958 
from PC1 (top high and low rotation genes analysed using the Likelihood ratio 959 
test (LRT) as well as the intensity difference test).  960 
eMPC, embryonic mammary progenitor cell; MP3, mammary primordium 3; 961 
BME, basement membrane extract; PC, principal component, MPE, 962 
mammary primordial epithelium, Epi, epithelium, MM, mammary 963 
mesenchyme, FPP, future fat pad precursor. ESC, embryonic stem cells, 964 
MEF, mouse embryonic fibroblasts, MSC, mesenchymal stem cells and 965 
BMMC, bone marrow mononuclear cells. Early and late indicate clones that 966 
were sequenced at early (5th) and later (13th) passage. 967 
 968 
Figure 3. Progenitor and lineage-associated marker expression in select 969 
eMPCs. 970 
(A) Heatmap depicting stem cell and epithelial marker expression in four 971 
eMPC selected for further characterisation.  972 
(B) qRT-PCR for Aldh1a1, Krt19, Krt18, Sox9, Snai2, Twist1, Procr, Trp63, 973 
Fabp4 in eMPC clones. Relative quantification (RQ) of each sample is 974 
normalised to that of ePool and shown in log2 plot with error bar of triplicates. 975 
(n = 3, mean ± s.e.m.). 976 
(C) Immunohistochemistry staining of Sox9 and Twist expression in eMPC. 977 
Scale bar, 200 μm. 978 
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eMPC, embryonic mammary progenitor cell; MEF, mouse embryonic 979 
fibroblast; MSC, mesenchymal stem cell; ESC, embryonic stem cell. 980 
 981 
Figure 4. eMPCs harbour varying potential for differentiation into 982 
mesodermal lineage. 983 
(A) In vitro differentiation of eMPC clones and positive control (MSC) with 984 
adipogenic stimuli. Neutral lipid staining merged with bright-field image shows 985 
accumulation of lipid droplets (red) within cells after 6 days of induction. Scale 986 
bar, 100 μm.  987 
(B) Vasculogenesis assay results of eMPCs and positive control (HUVEC). 988 
Tubes formed in medium with growth factors (EGM) and without growth 989 
factors were stained with Calcein AM (white) after 24 hours incubation. The 990 
total area of networks (blue, yellow, and green lines) was analysed and 991 
presented in box plots with whiskers denoting minimum and maximum values 992 
(n = 4 mean ± s.e.m.). Statistical significance was computed using one-way 993 
ANOVA and Dunnett’s multiple comparisons test as ****P ≤ 0.0001, P*** ≤ 994 
0.001, ns = no significance. Two-tailed P values are ePool EGM 0.0001, e1 995 
EGM 0.0001, e2 EGM 0.1607, eG1 EGM 0.9994, eG2 EGM 0.0005, MSC 996 
EGM 0.9999, and HUVEC EGM 0.0001, when compared to control HUVEC 997 
EBM. Scale bar, 200 μm. 998 
eMPC, embryonic mammary progenitor cell; MSC, mesenchymal stem cell; 999 
HUVEC, Human umbilical vein endothelial cells; EGM, endothelial cell growth 1000 
media EBM, endothelial basal growth media.  1001 
 1002 
Figure 5. eMPC lines are clonogenic and display distinct acinar 1003 
morphologies when grown as mammopheres in 3-D culture. 1004 
(A) Bright-field images of single cell-derived spheres. Scale, 40 μm.  1005 
(B) Colony-formation ability presented in box plots with whiskers denoting 1006 
minimum and maximum values showing number of cells (out of 10,000 cells 1007 
plated) that gave rise to spheres in anchorage-independent cultures. 1008 
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Statistical significance was computed for each cell line compared to control 1009 
(MSC) using one-way ANOVA and Dunnett’s multiple comparisons test, 1010 
where ****P ≤ 0.0001, ** P ≤ 0.01, *P ≤ 0.05, ns = not significant. Two-tailed P 1011 
values are ePool 0.0152, e1 0.0001, e2 0.3582, eG1 0.0092, and eG2 0.1107 1012 
when compared to control MSC. (n = 3 mean ± s.e.m.).  1013 
(C) Compactness of individual spheres presented where a circle with Form 1014 
factor = 1 is most condensed. eG1 forms more compact spheres compared to 1015 
those of e1, which is also evident in images in (A). Statistical significance was 1016 
computed using unpaired t-test, where two-tailed ****P = 0.0001. Bar 1017 
indicates mean value ±  s.e.m. n = 3. 1018 
(D) Images of e1 and eG1 spheres stained by immunofluorescence with 1019 
CD44 (red), an adhesion receptor expressed by basal mammary cells which 1020 
mediates epithelial-stromal and cell-cell interactions and DAPI (blue). 1021 
Scale bar, 50 μm. 1022 
eMPC, embryonic mammary progenitor cell;  MSC, mesenchymal stem cell. 1023 
 1024 
Figure 6. eMPCs have lactogenic potential. 1025 
(A) Alveologenesis assay results for eMPC clones and positive control (MEC). 1026 
Formation of alveolar-like structures and milk production was assessed by 1027 
morphological changes  using bright-field microscopy, as well as IF using anti-1028 
milk antibody (red). Scale bar, 40 μm.  1029 
(B) Quantification of number of alveolar-like structures greater than 100 μm. 1030 
The plot is shown as count per 24 well. (n = 3, mean ±  s.e.m.). 1031 
eMPC, embryonic mammary progenitor cell; MEC (mammary epithelial cell). 1032 
 1033 
Figure 7. Loss of Sox9 in e1 enhances colony formation ability and 1034 
alters sphere morphology. 1035 
(A) Schematic illustration for establishment of Sox9-targeted subclones from 1036 
Cas9-expressing e1.  1037 
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(B) qRT-PCR for Sox9 and EMT regulator, Zeb1. Each RQ is normalised to 1038 
Co#1. Statistical significance between control group and Sox9 knockout group 1039 
was computed using unpaired t-test. **P ≤ 0.01, *P ≤ 0.05. Two-tailed P 1040 
values are 0.0306 for Sox9 and 0.0036 for Zeb1, respectively (n = 3, mean 1041 
with 95% confidence interval). 1042 
(C) Immunohistochemistry for Sox9 and Zeb1 showing Zeb1 expression is 1043 
decreased by Sox9 reduction. Scale, 200 μm.  1044 
(D) Representative images of spheres grown in methylcellulose (left) and 1045 
colony-formation ability presented in box plots (right) with minimum and 1046 
maximum values showing number of control or Sox9-targeted cells (out of 1047 
10,000 cells plated) that gave rise to spheres in anchorage-independent 1048 
cultures.  Statistical significance was calculated using unpaired t-test. Two-1049 
tailed ****P = 0.0001. (n = 3, mean ± s.e.m.). Scale bar , 100 μm. 1050 
(E) Representative images of spheroids grown in BME from control and Sox9-1051 
targeted cells.  Scale bar, 400 μm. 1052 
(F) Quantification of area of spheroids and (G) increase in area of protrusions 1053 
from spheroids grown in BME from e1/control and e1Sox9-KO cells. (n = 8, 1054 
mean + S.D.) Statistical significance was calculated using one-way ANOVA 1055 
and multiple comparisons, *** P=0.0002 in F and G. 1056 
e1, embryonic mammary progenitor cell 1; Co, control, non-targeted cells; KO, 1057 
knockout; Sox9-targeted cells; MEC, mammary epithelial cell. 1058 
 1059 
Figure 8. Effect of Sox9 ablation on embryonic mammary progenitor cell 1060 
fate and function. 1061 
 (A) qRT-PCR for Sox9, Zeb1, Snai2, Twist, Procr, Trp63, Acta2, and Ecad in 1062 
e1/Co#1 and e1/Sox9-KO#1 cells. Relative quantification of each sample is 1063 
normalised to that of e1/Co#1 and shown in Log2 plot with error bar of 1064 
triplicates. (n = 3, mean ± s.e.m.). 1065 
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(B) Heat map from RNA-seq of e1/control and e1/Sox9-KO cells of genes that 1066 
were significantly up- or down-regulated in all three e1/Sox9-KO subclones 1067 
using both DESeq and Intensity Difference test. 1068 
(C) In vitro alveologenesis assay results. Formation of alveoli-like structure 1069 
and milk production was assessed by morphological changes  using bright-1070 
field microscopy, as well as IF using anti-milk antibody (red) and DAPI. Scale 1071 
bar, 200 μm.  1072 
(D) In vitro alveologenesis assay results. Quantification of number of alveoli 1073 
less than 200 μm, 200-400 μm, and greater than 400 μm per well. Statistical 1074 
significance between control group and Sox9 knockout group  was  computed 1075 
using two-tailed paired t-test. P = 0.0044. (n = 3). 1076 
e1, embryonic mammary progenitor cell; Co#1/#2, control #1/#2, non-targeted 1077 
e1 cells; KO#1/#2/#3, knockout #1, #2, #3; Sox9-targeted e1 cells. 1078 
 1079 
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